Boettcher Lab

1/🔥 New paper from our lab! #TP53-mutant clonal hematopoiesis (#CH) greatly increases risk for therapy-related #AML/MDS - but why? We set out to dissect how mono- vs. biallelic #TP53 mutations drive leukemic evolution. nature.com/articles/s4137…

@myllymaki_mikko @Syopasaatio @LaaketieteenS @SuomenAkatemia @helsinkiuni Congratulations, Mikko! Well deserved! Looking forward to all the great science!

I would also like to thank our funders for their ongoing support. @Syopasaatio @LaaketieteenS @SuomenAkatemia @helsinkiuni

My research group has joined the Institute for Molecular Medicine Finland (FIMM)! Looking forward to continuing our work on clonal hematopoiesis and grateful for the opportunity to be part of this wonderful research community. @FIMM_UH @HiLIFE_helsinki helsinki.fi/en/hilife-hels…

Welcome to #ESHAL2026! Stay tuned! ESH Young Scientific Reporters @DKotsos & @TanMeg9595 will provide regular updates on the conference! February 27-March 1, 2026 Chairs: @DombretHerve, Christoph Röllig, @DrWendyStock #ESHCONFERENCES #leusm @Hemasphere_EHA

Getting started for #ESHAL2026 @ESHaematology.

Now online in @CD_AACR: Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators - by @FerranFeceCruz, @AndreasVarkaris, @aparna1024, Ryan Corcoran, and colleagues doi.org/10.1158/2159-8… @MassGenBrigham @MGBResearchNews @harvardmed

@brummendorf Thank you so much, Tim!

@TheBoettcherLab Congratulations, Steffen. Great work and great summary here !

1/🔥 New paper from our lab! #TP53-mutant clonal hematopoiesis (#CH) greatly increases risk for therapy-related #AML/MDS - but why? We set out to dissect how mono- vs. biallelic #TP53 mutations drive leukemic evolution. nature.com/articles/s4137…

@SanjayPatelMD Thank you so much for putting these findings in context! I have the impression that even when formal AEL criteria aren’t met, TP53-mutant myeloid neoplasms often show erythroid-dominant marrow findings. IMHO an under-appreciated pattern.

@TheBoettcherLab Such important work and interesting findings! By a completely different approach we have also observed conspicuous erythroid-lineage skewing in TP53m MDS (doi.org/10.1101/2025.1…) - reassuring to see this pattern emerge in your studies!

@DrKTakahashi Thank you so much!

@TheBoettcherLab Congratulations! Beautiful study!

8/🍾🎉 Congratulations to #JonasFullin and the entire team, and many thanks to all collaborators! 📄 Read the full paper here: “The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis” nature.com/articles/s4137…

7/🎯 Take-home message: Biallelic #TP53 inactivation is the key driver of leukemic transformation from CH → t-AML/MDS. Non-mutational p53 inactivation matters (as recently shown #PMID: 40315418) Findings support biallelic #TP53-mutant AML/MDS as a distinct biological entity.

@to123w Congratulations, Tobias! Fantastic news!

Thrilled to share that I have been awarded an ERC Starting Grant Hashtag#ERCStG! With this, we aim to push the boundaries of cancer immunotherapy for patients with brain tumors. Very grateful to my team & collaborators and looking forward to the next steps ahead of us!🙏

@AlejoFraticelli Unexpected?🤣

One of the unexpected pleasures of parenting - lice removal… 🪲🪲🪲

The progression from BMF to MDS/AML Dr Jean Soulier

@AlejoFraticelli @LWahlster @Nature @CRGenomica Congratulations, Alejo! Great work!👏🎉🍾

Absolutely thrilled to share with you the final version of EPIclone, out now (open access) in @Nature. This has been an amazing collaboration with the lab of Lars Velten (@larsplus) at @CRGenomica nature.com/articles/s4158…

REGISTER NOW! 🚨🚨 Spots are filling up for the first EMBO workshop on Single cell Lineage Tracing 2025!! Sept 18-21 in Girona, Spain. Tons of opportunities for talks (short and full length) still available!!! meetings.embo.org/event/25-linea…